Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Drug Targets
  4. Fast Track Articles
  5. Fast Track Article
image of Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review

Abstract

The most prevalent histologic subtype of primary liver cancer, hepatocellular carcinoma, is also the third most lethal malignancy worldwide and a significant cause of cancer death. When diagnosed, it is frequently too late for curative therapies. To add to the difficulty, it is resistant to conventional systemic therapies like chemotherapy.

Recently, more attention has been given to the use of immunotherapy for this condition. Immunotherapy has had a major impact on the outcome of several malignancies; several studies have revealed the potential role of immunotherapy in advanced hepatocellular carcinoma. To provide an overview of the current literature, justification, and clinical evidence for the use of immunotherapy in advanced hepatocellular carcinoma, we employed a systematic literature review (SLR) approach in this work. Additionally, we explored the benefits and rationales of various treatment combinations and described the molecular mechanisms behind resistance to a number of immunotherapy drugs.

A total of 188 articles from credible journals published between 2013 and August 7, 2023, were screened. Eight of those articles were chosen for in-depth study. This systematic review concluded that the current immunotherapeutic approaches have the potential to improve outcomes for aHCC patients; however, several clinical and biological hurdles have to be overcome, and predictive markers are still eagerly needed.

To fully realize the potential of immunotherapy agents and their combination therapies to enhance health outcomes for patients with aHCC, additional investigation and research are required.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096309235240827052642
2024-10-07
2025-01-18

  • From This Site

    /content/journals/ccdt/10.2174/0115680096309235240827052642
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Rumgay H. Arnold M. Ferlay J. Lesi O. Cabasag C.J. Vignat J. Laversanne M. McGlynn K.A. Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 2022 77 6 1598 1606 10.1016/j.jhep.2022.08.021 36208844
    [Google Scholar]
  2. Janevska D. Chaloska-Ivanova V. Janevski V. Hepatocellular carcinoma: Risk factors, diagnosis and treatment. Open Access Maced. J. Med. Sci. 2015 3 4 732 736 10.3889/oamjms.2015.111 27275318
    [Google Scholar]
  3. Reig M. Forner A. Rimola J. Ferrer-Fàbrega J. Burrel M. Garcia-Criado Á. Kelley R.K. Galle P.R. Mazzaferro V. Salem R. Sangro B. Singal A.G. Vogel A. Fuster J. Ayuso C. Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022 76 3 681 693 10.1016/j.jhep.2021.11.018 34801630
    [Google Scholar]
  4. Sun V.C. Sarna L. Symptom management in hepatocellular carcinoma. Clin. J. Oncol. Nurs. 2008 12 5 759 766 10.1188/08.CJON.759‑766 18842532
    [Google Scholar]
  5. Chen S. Du Y. Guan X.Y. Yan Q. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Front. Oncol. 2023 13 1204513 10.3389/fonc.2023.1204513 37576900
    [Google Scholar]
  6. Federico P. Petrillo A. Giordano P. Bosso D. Fabbrocini A. Ottaviano M. Rosanova M. Silvestri A. Tufo A. Cozzolino A. Daniele B. Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives. Cancers 2020 12 10 3025 10.3390/cancers12103025 33080958
    [Google Scholar]
  7. Griffiths C.D. Zhang B. Tywonek K. Meyers B.M. Serrano P.E. Toxicity profiles of systemic therapies for advanced hepatocellular carcinoma. JAMA Netw. Open 2022 5 7 e2222721 10.1001/jamanetworkopen.2022.22721 35849393
    [Google Scholar]
  8. Ryoo B.Y. Merle P. Kulkarni A.S. Cheng A.L. Bouattour M. Lim H.Y. Breder V. Edeline J. Chao Y. Ogasawara S. Yau T. Garrido M. Chan S.L. Daniele B. Norquist J.M. Chen E. Siegel A.B. Zhu A.X. Finn R.S. Kudo M. Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma. Cancer 2021 127 6 865 874 10.1002/cncr.33317 33231873
    [Google Scholar]
  9. Gao Y. Guo J. Bao X. Xiong F. Ma Y. Tan B. Yu L. Zhao Y. Lu J. Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial. Oncologist 2021 26 11 e1919 e1930 10.1002/onco.13899 34255901
    [Google Scholar]
  10. Ziogas I.A. Evangeliou A.P. Giannis D. Hayat M.H. Mylonas K.S. Tohme S. Geller D.A. Elias N. Goyal L. Tsoulfas G. The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2,402 patients. Oncologist 2021 26 6 e1036 e1049 10.1002/onco.13638 33314549
    [Google Scholar]
  11. Gao P. Ding G. Wang L. The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis. Transl. Cancer Res. 2021 10 10 4290 4302 10.21037/tcr‑21‑905 35116288
    [Google Scholar]
  12. Zhang Y.L. Cui X.J. Xing H. Ning H.F. Dong P. Wang G.Z. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis based on randomized controlled trials. Ann. Med. 2023 55 2 2242384 10.1080/07853890.2023.2242384 37557186
    [Google Scholar]
  13. Fessas P. Naeem M. Pinter M. Marron T.U. Szafron D. Balcar L. Saeed A. Jun T. Dharmapuri S. Gampa A. Wang Y. Khan U. Muzaffar M. Navaid M. Lee P.C. Bulumulle A. Yu B. Paul S. Nimkar N. Bettinger D. Hildebrand H. Abugabal Y.I. Pressiani T. Personeni N. Nishida N. Kudo M. Kaseb A. Huang Y.H. Ang C. Pillai A. Rimassa L. Naqash A.R. Sharon E. Cortellini A. Pinato D.J. Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. Liver Cancer 2021 10 6 583 592 10.1159/000519108 34950181
    [Google Scholar]
  14. Rizzo A. Ricci A.D. Fanizzi A. Massafra R. De Luca R. Brandi G. Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A meta-analysis. Curr. Oncol. 2023 30 1 749 757 10.3390/curroncol30010057 36661706
    [Google Scholar]
  15. Oura K. Morishita A. Tani J. Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: A review. Int. J. Mol. Sci. 2021 22 11 5801 10.3390/ijms22115801 34071550
    [Google Scholar]
  16. Zhang P. Wen F. Li Q. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. Dig. Liver Dis. 2016 48 12 1492 1497 10.1016/j.dld.2016.07.007 27486048
    [Google Scholar]
  17. Binnewies M. Roberts E.W. Kersten K. Chan V. Fearon D.F. Merad M. Coussens L.M. Gabrilovich D.I. Ostrand-Rosenberg S. Hedrick C.C. Vonderheide R.H. Pittet M.J. Jain R.K. Zou W. Howcroft T.K. Woodhouse E.C. Weinberg R.A. Krummel M.F. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018 24 5 541 550 10.1038/s41591‑018‑0014‑x 29686425
    [Google Scholar]
  18. Shiravand Y. Khodadadi F. Kashani S.M. Hosseini-Fard S.R. Hosseini S. Sadeghirad H. Ladwa R. O’Byrne K. Kulasinghe A. Immune checkpoint inhibitors in cancer therapy. Curr. Oncol. 2022 29 5 3044 3060 10.3390/curroncol29050247 35621637
    [Google Scholar]
  19. Yau T. Kang Y.K. Kim T.Y. El-Khoueiry A.B. Santoro A. Sangro B. Melero I. Kudo M. Hou M.M. Matilla A. Tovoli F. Knox J.J. Ruth He A. El-Rayes B.F. Acosta-Rivera M. Lim H.Y. Neely J. Shen Y. Wisniewski T. Anderson J. Hsu C. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. JAMA Oncol. 2020 6 11 e204564 10.1001/jamaoncol.2020.4564 33001135
    [Google Scholar]
  20. Kelley R.K. Abou-Alfa G.K. Bendell J.C. Kim T.Y. Borad M.J. Yong W.P. Morse M. Kang Y.K. Rebelatto M. Makowsky M. Xiao F. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J. Clin. Oncol. 2017 35 10.1200/JCO.2017.35.15_suppl.4073
    [Google Scholar]
  21. Finn R.S. Qin S. Ikeda M. Galle P.R. Ducreux M. Kim T.Y. Kudo M. Breder V. Merle P. Kaseb A.O. Li D. Verret W. Xu D.Z. Hernandez S. Liu J. Huang C. Mulla S. Wang Y. Lim H.Y. Zhu A.X. Cheng A.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 2020 382 20 1894 1905 10.1056/NEJMoa1915745 32402160
    [Google Scholar]
  22. Wu S.J. Ruan D.D. Wu Q.Y. Tang Y. Zhang J.H. Cai S.L. Zhou Y.F. Luo J.W. Fang Z.T. Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with lenvatinib and anti-pd-1 antibodies for unresectable hepatocellular carcinoma: A retrospective analysis. J. Hepatocell. Carcinoma 2023 10 807 820 10.2147/JHC.S408819 37292114
    [Google Scholar]
  23. Huang J.T. Zhong B.Y. Jiang N. Li W.C. Zhang S. Yin Y. Yang J. Shen J. Wang W.S. Zhu X.L. Chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma. J. Hepatocell. Carcinoma 2022 9 1217 1228 10.2147/JHC.S386672 36474670
    [Google Scholar]
  24. de la Torre-Aláez M. Matilla A. Varela M. Iñarrairaegui M. Reig M. Lledó J.L. Arenas J.I. Lorente S. Testillano M. Márquez L. Da Fonseca L. Argemí J. Gómez-Martin C. Rodriguez-Fraile M. Bilbao J.I. Sangro B. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: A phase 2, single-arm study. J. Immunother. Cancer 2022 10 11 e005457 10.1136/jitc‑2022‑005457 36450386
    [Google Scholar]
  25. Somasundaram A. Helft P.R. Harris W.P. Sanoff H.K. Johnson G.E. Yu M. Johnson M. O'Neil B. McRee A.J. A study of pembrolizumab (pembro) in combination with Y90 radioembolization in patients (pts) with poor prognosis hepatocellular carcinoma (HCC). J. Clini. Oncol. 2023 41 4 10.1200/JCO.2023.41.4_suppl.534
    [Google Scholar]
  26. Yi M. Li T. Niu M. Wu Y. Zhao Z. Wu K. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Front. Immunol. 2022 13 1061394 10.3389/fimmu.2022.1061394 36601124
    [Google Scholar]
  27. Hoseini S.S. Cheung N.K. Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett. 2017 399 44 52 10.1016/j.canlet.2017.04.013 28428075
    [Google Scholar]
  28. Rochigneux P. Chanez B. De Rauglaudre B. Mitry E. Chabannon C. Gilabert M. Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials. Cancers 2021 13 2 271 10.3390/cancers13020271 33450845
    [Google Scholar]
  29. Yang C.K. Huang C.H. Hu C.H. Fang J.H. Chen T.C. Lin Y.C. Lin C.Y. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma. PLoS One 2023 18 1 e0280023 10.1371/journal.pone.0280023 36598909
    [Google Scholar]
  30. Takayama T. Sekine T. Makuuchi M. Yamasaki S. Kosuge T. Yamamoto J. Shimada K. Sakamoto M. Hirohashi S. Ohashi Y. Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000 356 9232 802 807 10.1016/S0140‑6736(00)02654‑4 11022927
    [Google Scholar]
  31. Zheng X. Jin W. Wang S. Ding H. Progression on the roles and mechanisms of tumor-infiltrating t lymphocytes in patients with hepatocellular carcinoma. Front. Immunol. 2021 12 729705 10.3389/fimmu.2021.729705 34566989
    [Google Scholar]
  32. Sajid M. Liu L. Sun C. The dynamic role of nk cells in liver cancers: role in hcc and hbv associated hcc and its therapeutic implications. Front. Immunol. 2022 13 887186 10.3389/fimmu.2022.887186 35669776
    [Google Scholar]
  33. Rico Montanari N. Anugwom C.M. Boonstra A. Debes J.D. The role of cytokines in the different stages of hepatocellular carcinoma. Cancers 2021 13 19 4876 10.3390/cancers13194876 34638361
    [Google Scholar]
  34. Rubie C. Frick V.O. Wagner M. Rau B. Weber C. Kruse B. Kempf K. Tilton B. König J. Schilling M. Enhanced expression and clinical significance of CC-chemokine MIP-3 α in hepatocellular carcinoma. Scand. J. Immunol. 2006 63 6 468 477 10.1111/j.1365‑3083.2006.001766.x 16764701
    [Google Scholar]
  35. Tojjari A. Saeed A. Singh M. Cavalcante L. Sahin I.H. Saeed A. A Comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma. Vaccines 2023 11 8 1357 10.3390/vaccines11081357 37631925
    [Google Scholar]
  36. Amin A. Awad B. Crocin-sorafenib combination therapy for liver cancer. U.S 10933076B2, 2020
  37. Amin A. Prevention of liver cancer with safranal-based formulations. U.S 10912741B2, 2020
  38. Amin A. Almansoori A. Balg B. Safranal-sorafenib combination therapy for liver cancer. U.S 10568873B1, 2020
/content/journals/ccdt/10.2174/0115680096309235240827052642
Loading
Role of Immunotherapy in the Management of Advanced Hepatocellular Carcinoma: A Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/0115680096309235240827052642
/content/journals/ccdt/10.2174/0115680096309235240827052642
/content/journals/ccdt/10.2174/0115680096309235240827052642
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keywords: immunotherapy ; India ; advanced hepatocellular carcinoma ; vaccine therapy ; immune checkpoint inhibitors ; Adoptive cell therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test